> Skip repeated content

Department of Medicine

Research

Breakthrough research leads to improved patient care

Department of Medicine researchers have made important contributions to the development of novel therapies that are improving patient outcomes.

Clinical Trials by Condition

APS (Antiphospholipid Syndrome)

Clinical Trial
Principal Investigator
IRB #
APS ACTION (Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking) International Clinical Database and Repository.
Doruk Erkan, M.D
11180
Comparison of Gut Commensal Bacteria between Persistently Anti-beta2 Glycoprotein-1 Positive Patients and Antiphospholipid Antibody Negative Patients
Doruk Erkan, MD
12186
PROMISSE: Predictors of Pregnancy Outcome: Biomarkers in Anti-Phospholipid Antibody Syndrome (APS) and Systemic Lupus Erythematosus (SLE)
Jane E. Salmon, MD
22122
Autoimmune Disease Registry and Repository
Jane E. Salmon, MD
95004

Arthritis

Clinical Trial
Principal Investigator
IRB #
Lower Extremity Realignment Therapy for the Treatment of Medial Knee Osteoarthritis- A Pilot Study
Howard J. Hillstrom, PhD
28008
A Pilot Study of a Dexamethasone Implant System in Humans
Mark P. Figgie, MD
2015-523
The Established Rheumatoid Arthritis Cohort
Susan M. Goodman, MD
2014-234

Lupus

Clinical Trial
Principal Investigator
IRB #
A Multicenter, Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Doruk Erkan, MD, MPH
13190
Focus Groups to Gather Patient Preferences about the HSS Smartphone Application for Systemic Lupus Erythematosus
Alana B. Levine, MD
14008
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis: a Randomized, Controlled Phase 2 Open Label Multicenter Study
Kyriakos A. Kirou, MD
2015-038
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
Kyriakos A. Kirou, MD
2015-777
PROMISSE: Predictors of Pregnancy Outcome: Biomarkers in Anti-Phospholipid Antibody Syndrome (APS) and Systemic Lupus Erythematosus (SLE)
Jane E. Salmon, MD
22122
Fc Receptor Function in Normals and Systemic Lupus Erythematosus (SLE)
Jane E. Salmon, MD
93029
Autoimmune Disease Registry and Repository
Jane E. Salmon, MD
95004

Please visit the Mary Kirkland Center for Lupus Research and the Lupus Clinical Trials Consortium for more information on lupus research.

Scleroderma

Clinical Trial
Principal Investigator
IRB #
Scleroderma Cyclophosphamide or Transplantation (SCOT) Study
Robert F. Spiera, MD
26002
Gleevec in the Treatment of Systemic Sclerosis - EXTENSION STUDY
Robert F. Spiera, MD
28128
Scleroderma Registry and Repository (Old IRB #26069)
Robert F. Spiera, MD
2014-276
VCRC Genetic Repository One Time DNA Protocol - 2016
Robert F. Spiera, MD
2014-278
The Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension: a Multicenter Study Performed by from the Scleroderma Clinical Trials Consortium (PHAROS)
Jessica K. Gordon, MD
2014-265
Prospective Registry of Early Systemic Sclerosis (PRESS)- Phenotypic, Serologic, and Biomarker/Genetic Characteristics of Early Diffuse Cutaneous Scleroderma
Jessica K. Gordon, MD
2014-264
A Double Blind, Randomized, Placebo-Controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients with “Systemic Sclerosis associated Interstitial Lung Disease” (SSc-ILD)
Robert F. Spiera, MD
2015-390
The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
Robert F. Spiera, MD
13224
ASCI: A Randomized, Double-blind, Placebo-controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Robert F. Spiera, MD
13004
Phase II/III, Multicenter, Randomized, Double-blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab vs. Placebo in Patients with Systemic Sclerosis
Robert F. Spiera, MD
12136
Bellumimab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Robert F. Spiera, MD
12006
Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension
Jessica Gordon, MD
10115
Nilotinib in the Treatment of Systemic Sclerosis
Robert F. Spiera, MD
10041